Clinical Trial Update: Phase 3b Study to Evaluate Skeletal Response to Eliglustat in Adult Patients Who Completed Phase 2 or Phase 3 Studies [Phase 3]

View source ↗

Summary

Phase 3b trial update evaluating skeletal response to eliglustat in adults who completed prior studies for Gaucher disease; status completed with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gaucher Disease

Drugs mentioned

• Eliglustat (Eliglustat)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Gaucher Disease | Phase 3 | Status: COMPLETED | Results posted: 2022-07-15